Wealth Alliance Trims Position in Hologic, Inc. (NASDAQ:HOLX)

Wealth Alliance lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,315 shares of the medical equipment provider’s stock after selling 343 shares during the period. Wealth Alliance’s holdings in Hologic were worth $383,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in HOLX. FMR LLC increased its position in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the period. Nordea Investment Management AB increased its position in Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after purchasing an additional 544,889 shares during the period. Swedbank AB increased its position in Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares during the period. JPMorgan Chase & Co. increased its position in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after purchasing an additional 238,222 shares during the period. Finally, Barclays PLC increased its position in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock valued at $58,507,000 after purchasing an additional 231,578 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on HOLX shares. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Mizuho lowered their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Tuesday, November 5th. UBS Group raised their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Jefferies Financial Group began coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price for the company. Finally, BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $85.77.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $64.47 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $14.47 billion, a price-to-earnings ratio of 20.34, a PEG ratio of 2.13 and a beta of 0.97. The company has a 50 day simple moving average of $69.91 and a two-hundred day simple moving average of $76.61. Hologic, Inc. has a 12 month low of $62.69 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.